ImClone Erbitux Use And Company Strategy

Executive Summary

Editor's note: This story - which originally carried the headline "ImClone Erbitux Used By Nearly 80% Of Colorectal Cancer Patients" - contains an incorrect characterization of Erbitux usage in the overall colorectal cancer population. First-line colorectal cancer penetration for Bristol-Myers Squibb/ImClone's Erbitux (cetuximab) was in fact 4% in the fourth quarter of 2005. Second- and third-line penetration was 13% and 31%, respectively, ImClone said. Among the total number of patients using Erbitux, 82% were being treated for colorectal cancer.